211 related articles for article (PubMed ID: 28434305)
1. Transthyretin amyloidosis: a little history of hereditary amyloidosis.
Benson MD
Amyloid; 2017 Mar; 24(sup1):76-77. PubMed ID: 28434305
[No Abstract] [Full Text] [Related]
2. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
4. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
5. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
[No Abstract] [Full Text] [Related]
6. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
[TBL] [Abstract][Full Text] [Related]
7. Ocular manifestations in hereditary transthyretin Gly67Glu amyloidosis.
Leung KCP; Ko TCS
Amyloid; 2019 Sep; 26(3):171-172. PubMed ID: 31135236
[No Abstract] [Full Text] [Related]
8. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
[TBL] [Abstract][Full Text] [Related]
9. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
10. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
Niemietz C; Chandhok G; Schmidt H
Molecules; 2015 Sep; 20(10):17944-75. PubMed ID: 26437390
[TBL] [Abstract][Full Text] [Related]
11. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
12. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
[TBL] [Abstract][Full Text] [Related]
13. Inotersen treatment for ATTR amyloidosis.
Benson MD
Amyloid; 2019; 26(sup1):27-28. PubMed ID: 31343345
[No Abstract] [Full Text] [Related]
14. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.
Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS
Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
Gonçalves P; Martins H; Costelha S; Saraiva MJ
Amyloid; 2017 Mar; 24(sup1):38-39. PubMed ID: 28434297
[No Abstract] [Full Text] [Related]
17. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
18. Systemic angiopathy and axonopathy in hereditary transthyretin amyloidosis with Ala97Gly (p. Ala117Gly) mutation: a post-mortem analysis.
Koike H; Yasuda T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Sobue G; Katsuno M
Amyloid; 2018 Jun; 25(2):141-142. PubMed ID: 29855203
[No Abstract] [Full Text] [Related]
19. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
Goel V; Gosselin NH; Jomphe C; Zhang X; Marier JF; Robbie GJ
Nucleic Acid Ther; 2020 Jun; 30(3):143-152. PubMed ID: 32175804
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
